Phase 3Completed
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study
- Sponsor
- Assistance Publique - Hôpitaux de Paris (Academic or other)
- Enrolment
- 102 enrolled
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis
- Interventions
- Mepolizumab; cyclophosphamide/azathioprine; Placebo
- Ages
- adults, older adults
- Registry
- NCT05030155, EUCTR2020-003318-10
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
Primary outcomes
- Percentage of patients who achieved a prednisone dose of 4.0 mg or less per day at day 168, without experiencing a relapse
History
Last registry update
Study completion
Primary completion
Started
Registered